InvestSMART

Cyclopharm Limited (ASX: CYC) - Announcements

Current share price for CYC : $0.455 0.005 (1.11%)+

ASX company news and announcements for Cyclopharm Limited (CYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cyclopharm Limited (CYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cyclopharm Limited (CYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cyclopharm Limited (CYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$57 CYC Unaudited Trading Update - Preliminary FY2025 Results 2 Feb 2026 9:39AM $1.170 $0.455 fallen by 61.11%
$57 Trading Halt 2 Feb 2026 9:07AM $1.170 $0.455 fallen by 61.11%
$57 COPD Study Leveraging Technegas and AI-Driven Lung Analysis 29 Jan 2026 8:19AM $1.130 $0.455 fallen by 59.73%
$57 Technegas Recognised in Updated Clinical Guideline 27 Jan 2026 9:00AM $0.880 $0.455 fallen by 48.30%
$57 Insurer Indemnifies Cyclopharm 27 Jan 2026 8:27AM $0.880 $0.455 fallen by 48.30%
$57 Stanford Children's Health to Implement Technegas 12 Jan 2026 8:28AM $0.940 $0.455 fallen by 51.60%
$57 Colombia Approval Marks 67th Country for Technegas 22 Dec 2025 9:24AM $0.950 $0.455 fallen by 52.11%
$57 Technegas Asthma Trial Commences in Canada 21 Nov 2025 8:24AM $0.810 $0.455 fallen by 43.83%
$57 Cyclopharm Bell Potter Healthcare Conference Presentation 19 Nov 2025 8:30AM $0.665 $0.455 fallen by 31.58%
$57 Cyclopharm Completes Sale of Cyclotron Asset 12 Nov 2025 12:56PM $0.640 $0.455 fallen by 28.91%
$57 Legal Proceedings 7 Oct 2025 6:50PM $0.790 $0.455 fallen by 42.41%
$57 S&P DJI Announces September 2025 Quarterly Rebalance 5 Sep 2025 5:08PM $0.870 $0.455 fallen by 47.70%
$57 2025 Half-year Results Webinar Presentation 2 Sep 2025 10:50AM $0.975 $0.455 fallen by 53.33%
$57 Cyclopharm 1H2025 Results Webinar 27 Aug 2025 5:11PM $1.000 $0.455 fallen by 54.50%
$57 CYC 1H2025 Results Summary 27 Aug 2025 5:05PM $1.000 $0.455 fallen by 54.50%
$57 Half Yearly Report and Accounts 27 Aug 2025 4:49PM $1.000 $0.455 fallen by 54.50%
$57 CYC Appoints US Sales Vice President 16 Jul 2025 8:56AM $0.990 $0.455 fallen by 54.04%
$57 Cyclopharm Secures Maximum US Patent Extension for Technegas 11 Jun 2025 8:19AM $1.070 $0.455 fallen by 57.48%
$57 Results of AGM 30 May 2025 2:08PM $1.220 $0.455 fallen by 62.70%
$57 CYC 2025 AGM Presentation 30 May 2025 10:17AM $1.180 $0.455 fallen by 61.44%
$57 Managing Director's Address to Shareholders 30 May 2025 10:16AM $1.180 $0.455 fallen by 61.44%
$57 Chair's Address to Shareholders 30 May 2025 10:15AM $1.180 $0.455 fallen by 61.44%
$57 Notice of Annual General Meeting/Proxy Form 29 Apr 2025 4:20PM $1.140 $0.455 fallen by 60.09%
$57 Technegas Installed at First DoD Hospital 10 Apr 2025 10:46AM $1.105 $0.455 fallen by 58.82%
$57 Revised Date of Annual General Meeting 9 Apr 2025 10:19AM $1.190 $0.455 fallen by 61.76%

51 - 75 of 612 results

Page 3 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.